.Pharmacolibrary.Drugs.ATC.J.J01CR01

Information

Combination of ampicillin, a broad-spectrum penicillin antibiotic, and a beta-lactamase inhibitor (commonly sulbactam); used for the treatment of infections caused by susceptible bacteria, particularly where beta-lactamase producing strains are present. Approved and widely used clinically, especially in hospital settings for severe infections.

Pharmacokinetics

Adults, both sexes, general population with normal renal function receiving ampicillin/sulbactam intravenously.

References

1. Setiawan, E, et al., & Roberts, JA (2023). Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients. Clinical pharmacokinetics 62(4) 573–586. DOI:10.1007/s40262-023-01219-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36853585

2. Schouwenburg, S, et al., & Preijers, T (2025). A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta-Lactamase Inhibition. Clinical pharmacology and therapeutics 117(1) 193–202. DOI:10.1002/cpt.3423 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39205386

3. Soto, E, et al., & Marshall, S (2014). Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. British journal of clinical pharmacology 77(3) 509–521. DOI:10.1111/bcp.12232 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24102758

Revisions

• 06/2025 initial generated model